Abstract Previous studies have indicated that after COVID-19, symptoms can persist for up to 12 months after recovery; however, the data on this are still limited. The aim of this study was to assess the prevalence of cardiovascular symptoms at 3 and 12 months after COVID-19 and to assess whether cardiovascular co-morbidity before SARS-CoV-2 infection are the risk factors for the development of post-COVID syndrome in both hospitalized and non-hospitalized patients. This longitudinal study was based on medical data collected during visits at 3 and 12 months after COVID-19 infection. Sociodemographic data, chronic conditions, and the most common clinical symptoms at 3 and 12 months after the disease were assessed during these in-person visits. The following symptoms were assessed as cardiovascular: palpitations/arrhythmias, anginal symptoms, dyspnea, venous thromboembolism, peripheral edema, newly diagnosed arterial hypertension, fainting/unconsciousness. In total, 643 patients were enrolled in the final analysis. The majority of the study group were women (63.1%), and the median age of the participants was 52 years. During the analysis of the clinical picture, after 12 months, 65.7% (62.1% – 69.6%) of patients declared the presence of at least one clinical symptom of post-COVID syndrome. The most common complaints were asthenia - 45.7% (41.9% - 49.6%) of patients, and neurocognitive symptoms - 40.0% (36.0% - 40.1%) of patients. Cardiovascular symptoms in 60.1% (56.2% – 63.8%) at 3 month FU and in 33.9% pts (31.1% – 37.9%) at 12 months FU were found (Figure 1). In a multivariate analysis, female sex (OR 1.59,p=0.012) and severe COVID-19 infection (OR 2.94,p<0.001) were associated with the persistence of clinical symptoms up to 12 months after recovery. The history of coronary artery disease, hypertension and dyslipidemia has no impact on symptoms at 12 months after the COVID-19 (Figure 2). To conclude, cardiovascular symptoms are the most common at 3 and 12 months after SARS-CoV-2 infection. The most burdensome level of COVID-19 severity was a predictor of post-COVID syndrome, neurocognitive symptoms, and fatigue. Cardiovascular comorbidity seems has no impact for post-COVID symptoms.Figure 1Figure 2